Cagrilintide characterization: aggregation control for an amylin analog
Cagrilintide is a long-acting 37-amino-acid amylin analog (amylin receptor agonist) retaining the conserved Cys2–Cys7 disulfide and C-terminal amide of the amylin family. Like native amylin it is intrinsically fibrillation-prone — soluble-oligomer and aggregate control is the defining analytical challenge, and SV-AUC is the reference technique for exactly that regime.
What each method answers for cagrilintide
Obtain a c(s) sedimentation coefficient distribution under selected formulation and concentration conditions. Report relative signals for resolved groups and compare with SEC when relevant.
Compare far-UV CD spectra and estimate secondary structure where applicable. Near-UV fingerprints and apparent transition temperatures depend on signal quality and interpretable transitions.
Determine apparent pI and relative peak areas for resolvable species. Assigning a peak to a particular charge variant requires a reference material or independent structural evidence.
Scope an amylin receptor assay separately. An incretin component such as semaglutide can be evaluated with an applicable receptor assay.
Cagrilintide impurity standards
Cagrilintide has no listed items in the current catalog. For custom synthesis inquiries, share the target structure and quantity. Feasibility, salt form, purity and lead time are confirmed per project.
Cagrilintide characterization — common questions
Why is aggregation control the central quality attribute for cagrilintide?+
Amylin-family peptides fibrillate through soluble oligomer intermediates that SEC and visual inspection miss. SV-AUC quantifies those early species in free solution, making it the controlling assay for formulation selection and shelf-life justification.
Can you support CagriSema-style combination programs?+
Yes. We characterize cagrilintide and semaglutide individually — aggregation, conformation, charge and potency per component — with matched methods so combination-program data stay comparable across both molecules.
Do you offer cagrilintide impurity reference standards?+
Cagrilintide has no listed items in the current catalog. For custom synthesis inquiries, share the target structure and quantity. Feasibility, salt form, purity and lead time are confirmed per project.
How little material does a formulation screen need?+
The platform is low-consumption: SV-AUC, CD and cIEF share one sample set, so a few milligrams support a multi-condition formulation screen (buffer, pH, excipients) with aggregation and conformation readouts per condition.
What data package supports an amylin-analog development program?+
An ICH Q6B-aligned orthogonal set: soluble-oligomer and aggregate distribution (SV-AUC), conformational fingerprint and Tm (CD), charge-variant profile (cIEF) and a potency strategy agreed per program — consolidated into one integrated report.
Developing cagrilintide or another amylin analog?
Tell us about your molecule and formulation — we return a tailored characterization plan, with aggregation control at its core, within 2 business days.